Guidelines for the diagnosis and management of von Willebrand disease in Italy

Haemophilia

Volumn 8, Issue 5, 2002, Pages 607-621

  Federici, A B ^a,c   Castaman, G ^b   Mannucci, P M ^a  

^a UNIVERSITY OF MILAN   (Italy)

^b SAN BORTOLO HOSPITAL   (Italy)

^c NONE   (Italy)

Author keywords

Congenital von Willebrand disease; Desmopressin; Factor VIII von Willebrand factor concentrates; Genetic and molecular diagnosis; Von Willebrand factor

Indexed keywords

AMINOCAPROIC ACID; ANTIFIBRINOLYTIC AGENT; ANTIVIRUS AGENT; BLOOD CLOTTING FACTOR 8; BLOOD CLOTTING FACTOR 8 CONCENTRATE; DESMOPRESSIN; EMOCLOT; EMOSINT; ESTROGEN; FANHDI; FIBRIN; MINIRIN DDAVP; PLASMINOGEN; RISTOCETIN; THROMBOCYTE RECEPTOR; TRANEXAMIC ACID; VON WILLEBRAND FACTOR;

ANAMNESIS; ARTICLE; BLEEDING DISORDER; BLEEDING TIME; BLOOD ANALYSIS; BLOOD CLOTTING; BLOOD TRANSFUSION; DIAGNOSTIC ACCURACY; DIAGNOSTIC PROCEDURE; DISEASE ASSOCIATION; DISEASE CLASSIFICATION; DISEASE SEVERITY; DRUG MECHANISM; FLUSHING; HEADACHE; HEMOSTASIS; HUMAN; ITALY; PATIENT CARE; PHENOTYPE; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN INTERACTION; PROTEIN STRUCTURE; SIDE EFFECT; TACHYCARDIA; THROMBOCYTE ADHESION; THROMBOCYTE AGGLUTINATION; THROMBOCYTE COUNT; VON WILLEBRAND DISEASE;

EID: 0036733501     PISSN: 13518216     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2516.2002.00672.x     Document Type: Article

References (102)

1. Guidelines for the diagnosis and management of von Willebrand disease
2. Impact, diagnosis and treatment of von Willebrand Disease
3. Diagnosis and management of von Willebrand disease
4. Structure of von Willebrand factor and its function in platelet adhesion and thrombus formation
5. Factor VIII and von Willebrand Factor
6. A revised classification of von Willebrand disease
7. Von Willebrand disease from 1926-1983
8. Epidemiological investigation of the prevalence of von Willebrand disease
9. Prevalence of VWD among US adults
10. Prevalence of VWD in children: A multiethnic study
11. Von Willebrand factor and its disorders: An overview of recent molecular studies
12. Frequency of different types of VWD in the GDR
13. A study of VWD in Jordan
14. A relative high frequency of severe (type 3) VWD in Israel
15. The 20-year (1978-98) natural history of von Willebrand disease in Italy: A multicentre retrospective analysis on diagnosis and therapy in 1234 patients
16. von Willebrand's disease in Sweden
17. Prevalence of bleeding manifestations, hepatitis and alloantibodies to von Willebrand factor in 348 Iranian patients with type 3 von Willebrand disease
18. Heterogeneous abnormalities in the multimeric structure, antigenic properties, and plasma-platelet content of factor VIII/von Willebrand factor insubtypes of classic (type I) and variant (IIA) von Willebrand's disease
19. Heterogeneity of type I von Willebrand disease: Evidence for a subgroup with an abnormal von Willebrand factor
20. Ristocetin cofactor and collagen binding activities normalized to antigen levels for a rapid diagnosis of type 2 von Willebrand disease: Single center comparison of four different assays
21. Recessive inheritance of von Willebrand Disease type I
22. Characterization of the genetic defects in recessive Type 1 and Type 3 von Willebrand Disease Patients of Italian origin
23. Genetics of classic von Willebrand's disease. I. Phenotypic variations within families
24. Serial studies in von Willebrand disease: Variability versus 'variants'
25. On laboratory problems in diagnosing mild von Willebrand disease
26. Type I von Willebrand disease, subtype 'platelet low': Decreased platelet adhesion can be explained by low synthesis of von Willebrand factor in endothelial cells
27. The effect of ABO blood groups on the diagnosis of von Willebrand disease
28. von Willebrand disease and quantitative variation of von Willebrand factor
29. Dominant type 1 von Willebrand disease caused by mutated cysteine residues in the D3 domain of von Willebrand factor
30. Variant von Willebrand's disease. Characterization of two subtypes by analysis of multimeric composition of FVIII/vWF in plasma and platelets
31. Type II A VWD with apparent recessive inheritance
32. Gene defects in 150 unrelated French cases with type 2 von Willebrand disease. From the patient to the gene. INSERM Nerwork on Molecular Abnormalities in von Willebrand Disease
33. Impaired intracellular transport produced by a subset of type II A vWD mutations
34. Aberrant dimeriztion of von Willebrand factor as the result of mutations in the carboxy-terminal region. Identification of 3 mutations in members of 3 different families with type 2A (phenotype IID) von Willebrand disease
35. A molecular approach to the classification of von Willebrand disease
36. Heightened interaction between platelets and factor VIII/ von Willebrand factor in a new subtype of von Willebrand's disease
37. VWF synthesized by endothelial cells from a patient with type II B supports platelet adhesion normally but has an increased affinity for platelets
38. Heterogeneity in type II B vWD. Two unrelated cases with no family history and mild abnormalities of ristocetin-induced interactions between vWF and platelets
39. Thrombocytopenia associated with pregnancy in a patient with type II B VWD
40. Spontaneous platelet aggregation during pregnancy in a patient wit vWD type II B can be blocked by monoclonal antibodies to both platelet glycoproteins Ib and IIb/IIIa
41. Type II B Tampa: A variant of vWD with chronic thrombocytopenia, circulating platelet aggregates, and spontaneous platelet aggregation
42. A type 2B von Willebrand disease mutation (Ile546 - >Val) associated with an unusual phenotype
43. von Willebrand disease type B. A missense mutation selectively abolishes ristocetin-induced von Willebrand factor binding to platelet glycoprotein Ib
44. Identification of two mutations (Arg611Cys and Arg611His) in the A1 loop of Von Willebrand factor (VWF) responsible for type 2 von Willebrand disease with decreased platelet-dependent function of VWF
45. Type 2M-Milwaukee-1 von Willebrand disease: An in-frame deletion in the Cys509-Cys695 loop of the von Willebrand factor A1 domain causes deficient binding of von Willebrand factor to platelets
46. Type 2M von Willebrand disease: F606I and I662F mutations in the glycoprotein Ib binding domain selectively impair ristocetin- but not botrocetin-mediated binding of von Willebrand factor to platelets
47. von Willebrand's disease 'Vicenza' with larger than normal (supranormal) von Willebrand factor multimers
48. von Willebrand disease type 2M 'Vicenza' in Italian and German patients: identification of the first candidate mutation (G3864A: R1205H) in 8 families
49. New variant of von Willebrand disease with defective binding to factor VIII
50. A new vWF defect in a patient with FVIII deficiency but with normal level and multimeric patterns of both plasma and platelet vWF. Characterization of abnormal vWF/FVIII interaction
51. Type 2N von Willebrand disease: Clinical manifestations, pathophysiology, laboratory diagnosis and molecular biology
52. Precipitating antibodies to FVIII/von Willebrand factor in von Willebrand disease: Effects on replacement therapy
53. Gene deletion correlates with the development of alloantibodies in von Willebrand disease
54. Life-threatening reaction to FVIII concentrate in a patient with severe vWD and alloantibodies to von Willebrand Factor
55. Posttransfusion anaphylactic reaction in a patient with severe von Willebrand disease: Role of complement and alloantibodies to von. Willebrand Factor
56. Nonsense mutations in the von Willebrand factor gene in patients with von Willebrand disease type III and type I
57. Characterization of the von Willebrand factor (VWF) gene in von Willebrand disease type III patients from 24 families of Swedish and Finnish origin
58. Genetic heterogeneity of severe von Willebrand disease type III in the German population
59. Effects of the mutant von Willebrand fcator gene in von Willebrand disease
60. Molecular characterization of a multiethnic group of 21 Patients with type 3 von Willebrand Disease
61. Pseudo-von Willebrand disease. An intrinsic platelet defect with aggregation by unmodified human factor VIII-von Willebrand factor and enhanced adsorption of its high-molecular-weight multimers
62. Platelet-type von Willebrand disease: Characterization of a new bleeding disorder
63. Acquired von Willebrand's disease: From pathophysiology to management
64. Acquired von Willebrand's syndrome in systemic lupus erythematosus
65. Studies of the pathophysiology of acquired von Willebrand's disease in seven patients with lymphoproliferative disorders or benign monoclonal gammopathies
66. Acquired von Willebrand Syndrome: Data from an International Registry
67. von Willebrand disease: A database of point mutation, insertions and deletions
68. A database of polymorphisms in the von Willebrand factor gene and pseudogene
69. Family studies and prenatal diagnosis in severe von Willebrand disease by polymerase chain reaction amplification of a variable number tandem repeat region of the von Willebrand factor gene
70. Report on a joint WHO/WFH meeting on the control of haemophilia: Carrier detection and prenatal diagnosis
71. Prenatal evaluation of fetus at risk for severe von Willebrand disease
72. Optimizing therapy with factor VIII/von Willebrand factor concentrates in von Willebrand disease
73. Management of inherited von Willebrand disease
74. The release of plasminogen activator and factor VIII by LVP, AVP, DDAVP, ATIII and OT in man
75. A new pharmacological approach to the management of hemophilia and von Willebrand disease
76. Clinical indications for desmopressin (DDAVP) in congenital and acquired von Willebrand disease
77. Consistency of responses to repeated DDAVP infusions in patients with von Willebrand disease and haemophilia A
78. Hyponatremia and seizures in young children given DDAVP
79. Myocardial infarction in a patient with hemophilia A treated with DDAVP
80. Thrombosis following desmopressin for uremic bleeding
81. Platelet aggregation induced by 1-desamino-8-D-arginine vasopressin (DDAVP) in type II B von Willebrand disease
82. DDAVP for type IIB von Willebrand disease
83. Platelet aggregation and pseudothrombocytopenia induced by 1-desamino-8-D-arginine vasopressin (DDAVP) in type II B von Willebrand disease
84. Collaborative Group. Biological effect of desmopressin in eight patients with type 2 N ('Normandy') von Willebrand disease
85. Correction of the hemostatic defects in von Willebrand disease
86. Replacement therapy with virus-inactivated plasma concentrates in von Willebrand disease
87. Chromatographic preparation of a therapeutic highly purified von Willebrand factor concentrate from human cryoprecipitate
88. Biological effects of a S/D-treated, very high purity, von Willebrand factor concentrate in five patients with severe von Willebrand Disease
89. Optimizing therapy of von Willebrand Disease with a safe and pure von Willebrand factor concentrate: The experience of the European Community
90. Use of a high-purity factor VIII concentrate (Hemate P) in von Willebrand's disease
91. The use of intermediate and high purity factor VIII products in the treatment of von Willebrand disease
92. Haemate P in children with von Willebrand disease
93. Experience with Haemate P in von Willebrand's disease in adults
94. Transfusion studies in von Willebrand disease: Effect on bleeding time and factor. VIII
95. Treatment of von Willebrand Disease with a high purity Factor VIII/von Willebrand factor concentrate in the treatment of von Willebrand disease: A prospective multicenter study
96. Comparison of four virus-inactivated plasma concentrates for treatment of severe von Willebrand disease: A cross-over randomized trial
97. Proteolysis of von Willebrand factor in therapeutic plasma concentrates
98. DDAVP shortens the prolonged bleeding time of patients with severe von Willebrand disease treated with cryoprecipitate. Evidence for a mechanism of action independent of released von Willebrand factor
99. Hemostatic effect of normal platelet transfusion in severe von Willebrand disease
100. Pregnancy in women with different types of von Willebrand disease